Li-Taka Pharmaceuticals Ltd, a Pune-based Pharmaceutical Formulation Company, has recently entered into Manufacturing Agreement with Wockhardt Ltd for manufacturing of Anti-TB range of products.
The Company is expected to receive incremental revenue of over Rs 6 million from this year, which shall further boost its revenues. The Company is already specialized in manufacture of Anti-TB range of products for large/multinational and Indian Companies such as Novartis/Cipla/Emcure/Lupin in the Anti-TB segment and this agreement with Wockhardt Ltd will add to the list of reputed clients for its contracts manufacturing business, Li-Taka said in a release to BSE.
The Exports division of the Company has succeeded in procuring registrations for several of its brands in Senegal, Venezuela, Panama and Kazakistan, the release added.